These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 23139702)

  • 1. Rituximab combination therapy in relapsing multiple sclerosis.
    Cross AH; Klein RS; Piccio L
    Ther Adv Neurol Disord; 2012 Nov; 5(6):311-9. PubMed ID: 23139702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.
    Naismith RT; Piccio L; Lyons JA; Lauber J; Tutlam NT; Parks BJ; Trinkaus K; Song SK; Cross AH
    Neurology; 2010 Jun; 74(23):1860-7. PubMed ID: 20530322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
    Piccio L; Naismith RT; Trinkaus K; Klein RS; Parks BJ; Lyons JA; Cross AH
    Arch Neurol; 2010 Jun; 67(6):707-14. PubMed ID: 20558389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MS and the B cell controversy.
    Cross AH; Waubant E
    Biochim Biophys Acta; 2011 Feb; 1812(2):231-8. PubMed ID: 20674743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autoreactive T and B cells in nervous system diseases.
    Sun JB
    Acta Neurol Scand Suppl; 1993; 142():1-56. PubMed ID: 8382894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting optimal response to B-cell depletion with rituximab in multiple sclerosis using CXCL13 index, magnetic resonance imaging and clinical measures.
    Alvarez E; Piccio L; Mikesell RJ; Trinkaus K; Parks BJ; Naismith RT; Cross AH
    Mult Scler J Exp Transl Clin; 2015; 1():2055217315623800. PubMed ID: 28607711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B Cell, Th17, and Neutrophil Related Cerebrospinal Fluid Cytokine/Chemokines Are Elevated in MOG Antibody Associated Demyelination.
    Kothur K; Wienholt L; Tantsis EM; Earl J; Bandodkar S; Prelog K; Tea F; Ramanathan S; Brilot F; Dale RC
    PLoS One; 2016; 11(2):e0149411. PubMed ID: 26919719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
    Stüve O; Cepok S; Elias B; Saleh A; Hartung HP; Hemmer B; Kieseier BC
    Arch Neurol; 2005 Oct; 62(10):1620-3. PubMed ID: 16216948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
    Hauser SL; Waubant E; Arnold DL; Vollmer T; Antel J; Fox RJ; Bar-Or A; Panzara M; Sarkar N; Agarwal S; Langer-Gould A; Smith CH;
    N Engl J Med; 2008 Feb; 358(7):676-88. PubMed ID: 18272891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients.
    Cross AH; Stark JL; Lauber J; Ramsbottom MJ; Lyons JA
    J Neuroimmunol; 2006 Nov; 180(1-2):63-70. PubMed ID: 16904756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.
    Sorensen PS; Blinkenberg M
    Ther Adv Neurol Disord; 2016 Jan; 9(1):44-52. PubMed ID: 26788130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
    Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
    Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of ionotropic glutamate receptor GLUR3 and effects of glutamate on MBP- and MOG-specific lymphocyte activation and chemotactic migration in multiple sclerosis patients.
    Sarchielli P; Di Filippo M; Candeliere A; Chiasserini D; Mattioni A; Tenaglia S; Bonucci M; Calabresi P
    J Neuroimmunol; 2007 Aug; 188(1-2):146-58. PubMed ID: 17628700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal study of antimyelin T-cell reactivity in relapsing-remitting multiple sclerosis: association with clinical and MRI activity.
    Hellings N; Gelin G; Medaer R; Bruckers L; Palmers Y; Raus J; Stinissen P
    J Neuroimmunol; 2002 May; 126(1-2):143-60. PubMed ID: 12020966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II baseline versus treatment study to determine the efficacy of raltegravir (Isentress) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI: The INSPIRE study.
    Gold J; Marta M; Meier UC; Christensen T; Miller D; Altmann D; Holden D; Bianchi L; Adiutori R; MacManus D; Yousry T; Schmierer K; Turner B; Giovannoni G
    Mult Scler Relat Disord; 2018 Aug; 24():123-128. PubMed ID: 29990894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association.
    Mantegazza R; Cristaldini P; Bernasconi P; Baggi F; Pedotti R; Piccini I; Mascoli N; La Mantia L; Antozzi C; Simoncini O; Cornelio F; Milanese C
    Int Immunol; 2004 Apr; 16(4):559-65. PubMed ID: 15039386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis.
    Karni A; Bakimer-Kleiner R; Abramsky O; Ben-Nun A
    Arch Neurol; 1999 Mar; 56(3):311-5. PubMed ID: 10190821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.